Fred Hutch

Radiation Therapy for Multiple Myeloma

Radiation therapy is a treatment that uses high doses of radiation to damage cancer cells, either killing them or slowing their growth. Unlike the low-dose radiation used in X-rays to see inside the ...
Business Wire

World’s First Cancer Patient Treated with RefleXion’s Breakthrough SCINTIX Biology-guided Radiotherapy

Radiopharmaceutical-directed treatment ushers in a new era of autonomous radiotherapy HAYWARD, Calif.--(BUSINESS WIRE)--RefleXion Medical, a therapeutic oncology company, today announced that the ...
ascopubs.org

Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial

Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial The following represents disclosure information ...
Business Wire

RefleXion Receives FDA Clearance for SCINTIX Biology-Guided Radiotherapy; Cutting-edge Treatment Applicable for Early and Late-stage Cancers

Each cancer’s unique biology provides second-by-second information to direct radiotherapy HAYWARD, Calif.--(BUSINESS WIRE)--RefleXion Medical, a therapeutic oncology company, today announced the U.S.
Nature

Flattening Filter Free Photon Beam Radiotherapy

The advent of flattening filter free (FFF) photon beam radiotherapy marks a significant evolution in external beam treatments. By removing the traditional flattening filter from linear accelerators, ...
MD&M East

First Cancer Patient Treated Using RefleXion’s Scintix Radiotherapy

RefleXion Medical, a therapeutic oncology company, has treated its first patient with Scintix biology-guided radiotherapy on the RefleXion X1 PET-CT machine. Scintix therapy is a ...
ascopubs.org

An observational study using γ-H2AX foci to investigate cardiac doses of radiation following adjuvant radiotherapy for breast cancer: Standard external beam radiotherapy to ...

TBCRC 019: An open-label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab in patients with ...